KURA

Kura Oncology, Inc.

13.15 USD

Last updated Sep 4, 21:03 UTC

Yesterday HIGH

$13.29

Yesterday LOW

$12.85

52w HIGH

$13.9

52w LOW

$7.36

EPS

-0.77

PE

-17.07

Next Earnings

Nov 3, 2026

Overview News Unusual Options Flow Insider Transactions Government Trades Fundamentals

Kura Oncology, Inc. stock is up 42.88% since 30 days ago. The next earnings date is Nov 3, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 54.55% of the previous 10 September’s closed higher than August. In the last 5 Unusual Options Trades, there were 2 PUTs, 3 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

17 Jul 17:04	18 Sep, 2026	17.00	PUT	180	0
28 Jul 18:23	18 Sep, 2026	17.00	PUT	45	315
25 Aug 19:36	18 Sep, 2026	14.00	CALL	1000	71
26 Aug 13:37	15 Jan, 2027	9.00	CALL	116	170
04 Sep 14:31	18 Sep, 2026	11.00	CALL	175	48

Advanced Data Unlock

Benzinga Newsdesk

Tue May 12, 2026

Kura Oncology Q1 EPS $(0.83) Beats $(0.94) Estimate, Sales $18.265M Miss $18.513M Estimate

Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.83) per share which beat the analyst consensus estimate of $(0.94) by 11.7 percent. This is a 25.76 percent decrease over losses of $(0.66) per share from the
Benzinga Newsdesk

Tue May 12, 2026

Kura Oncology Announces Acceptance Of Its Updated Results From Phase 1 KOMET-007 Clinical Study Of Ziftomenib In Combination With Cytarabine Plus Daunorubicin For Presentation At 2026 European Hematology Association Congress

Kura Oncology, Inc. (NASDAQ:KURA) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") today announced that updated results from the frontline arm of the Phase 1 KOMET-007 (NCT05735184) clinical trial evaluating
Benzinga Insights

Tue May 12, 2026

Earnings Scheduled For May 12, 2026
Benzinga Newsdesk

Fri Apr 24, 2026

Kyowa Kirin And Kura Oncology Announce First Patient Dosed In Japanese Phase 2 Registrational Clinical Trial Studying Ziftomenib For Treatment Of R/R NPM1-Mutated Acute Myeloid Leukemia

Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") and Kura Oncology, Inc. (NASDAQ:KURA, "Kura"))) today announced the first patient has been dosed in a Japanese Phase 2 registrational clinical trial (jRCT2031250550)
Vandana Singh

Fri Apr 17, 2026

Kura Oncology Advances Kidney Cancer Program With Solid Early-Stage Results

Kura Oncology says kidney cancer trial data shows 44% response rate and strong disease control; analysts maintain Buy ratings.
Benzinga Insights

Fri Apr 17, 2026

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Newsdesk

Fri Apr 17, 2026

Kura Oncology shares are trading higher after the company announced new preliminary data from a subset analysis of patients with clear cell renal cell carcinoma previously treated with cabozantinib in the ongoing FIT-001 clinical trial of darlifarnib in combination with cabozantin.
Benzinga Newsdesk

Fri Apr 17, 2026

Kura Oncology Says Darlifarnib Plus Cabozantinib Shows 44% ORR And 94% DCR In Cabozantinib-Pretreated ccRCC Patients In FIT-001 Study
Benzinga Newsdesk

Tue Apr 14, 2026

Lake Street Initiates Coverage On Kura Oncology with Buy Rating, Announces Price Target of $23

Lake Street analyst Daniel Brims initiates coverage on Kura Oncology (NASDAQ:KURA) with a Buy rating and announces Price Target of $23.
Benzinga Newsdesk

Thu Apr 9, 2026

Kura Oncology To Present Updated Data From FIT-001 Clinical Study Of Darlifarnib In Combination With Cabozantinib

Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced it will present updated data from its ongoing FIT-001 clinical trial (NCT

Citizens

Mon Aug 24, 15:05

buy

confirm
Wedbush

Thu Aug 13, 14:56

buy

confirm

Advanced Data Unlock

Troy E. Wilson, President and CEO

Mon Aug 24, 2026

KURA Recent Insider Trades and Stock Chart

100,000 shares bought
Brian Powl, Chief Commercial Officer

Fri Aug 21, 2026

KURA Recent Insider Trades and Stock Chart

4,345 shares sold
Teresa Bair, Chief Legal Officer

Wed Aug 19, 2026

KURA Recent Insider Trades and Stock Chart

31,487 shares sold
Troy E. Wilson, President and CEO

Mon Aug 17, 2026

KURA Recent Insider Trades and Stock Chart

100,000 shares bought